{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:59:55Z","timestamp":1788458395559,"version":"build-2803163510"},"reference-count":97,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Walter Schulz Stiftung"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["324392634\u2014TRR 221"],"award-info":[{"award-number":["324392634\u2014TRR 221"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Current therapies for neuroendocrine neoplasms (NENs) are limited, especially for fast-growing dedifferentiated NECs, which exhibit low somatostatin receptor (SSTR) expression and poor prognosis. Well-differentiated neuroendocrine tumors (NETs), on the other hand, retain SSTR expression, making them amenable to receptor-targeted therapies. In dedifferentiated NEC, C-X-C motif chemokine receptor 4 (CXCR4) has been shown to be abundantly expressed, making it a potential target for alternative treatment and diagnostic strategies. A major challenge in developing targeted therapies is the lack of primary patient-derived cell lines that maintain receptor profiles suitable for preclinical evaluation of established or innovative receptor-targeted approaches.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We established the MS-18 cell line from a metastatic rectal NEC. Neuroendocrine differentiation markers, SSTRs1\u20135, CXCR4, epithelial and mesenchymal markers, drug transporters (ABCB1, ABCG2), and Ki-67 were analyzed using qPCR and immunoblotting. Somatostatin receptor and CXCR4 function was evaluated by radiouptake assays. Electron microscopy, karyotyping, and CGH were performed, and the cell's in vivo engraftment rate was evaluated in a mouse NSG model. Viability studies on conventional therapeutic agents were performed. Extended molecular profiling of the primary tumor, liver metastasis, and MS-18 cell line was conducted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>MS-18 cells showed strong expression of neuroendocrine markers (synaptophysin, neuron-specific enolase) and preserved epithelial differentiation (high E-cadherin, absence of mesenchymal markers). SSTR1, SSTR2, and SSTR5 were highly expressed, while SSTR3 and SSTR4 were absent. Uniquely, MS-18 cells exhibited strong CXCR4 expression. The proliferation index (Ki-67: 90%) matched that of the primary tumor. Elevated ABCG2 expression contributed to resistance to etoposide. Molecular profiling revealed no pathogenic mutations in key genes commonly altered in NENs, including MEN1, DAXX, ATRX, mTOR, PTEN, TP53, and RB1. The successful in vivo engraftment rate was high (4\/5).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The MS-18 cell line is the first patient-derived cell line with a transitional phenotype between differentiated NET and dedifferentiated NEC, showing strong expression of SSTR2 and CXCR4 and absence of driver mutations in key NET-\/NEC-associated genes. It offers a unique platform for preclinical evaluation of targeted therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf159","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:50:14Z","timestamp":1758318614000},"page":"359-373","source":"Crossref","is-referenced-by-count":3,"title":["World first hybrid neuroendocrine cell line sharing properties of NET G3 and dedifferentiated NEC"],"prefix":"10.1093","volume":"193","author":[{"given":"Dorothee","family":"Rogoll","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Gastroenterology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-4176","authenticated-orcid":false,"given":"Laura-Sophie","family":"Landwehr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Endocrinology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schreiner","sequence":"additional","affiliation":[{"name":"Department of Endocrine Oncology, Ludwig-Maximilians-University, 80336 M\u00fcnchen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hartrampf","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Frey","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Meining","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Gastroenterology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gulden","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology\/Oncology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Schnaidt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology\/Oncology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szn Yi","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology\/Oncology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surasak","family":"Jittavisutthikul","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology\/Oncology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wen-Hui","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology\/Oncology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-2669","authenticated-orcid":false,"given":"Christian","family":"Stigloher","sequence":"additional","affiliation":[{"name":"Biocenter\/Theodor-Boveri-Institute, University of W\u00fcrzburg , 97074 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ludwig-Maximilians-University, 80336 M\u00fcnchen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scheurlen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Gastroenterology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bumm","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Endocrinology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4127-1347","authenticated-orcid":false,"given":"Alexander","family":"Weich","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Gastroenterology, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"1","key":"2025091917505474400_lvaf159-B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5694\/j.1326-5377.2010.tb03742.x","article-title":"Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management","volume":"193","author":"Modlin","year":"2010","journal-title":"Med J Aust"},{"issue":"2","key":"2025091917505474400_lvaf159-B2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2025091917505474400_lvaf159-B3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"2025091917505474400_lvaf159-B4","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1530\/ERC-13-0125","article-title":"Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature","volume":"21","author":"Fraenkel","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"S1","key":"2025091917505474400_lvaf159-B5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1530\/ERC-11-0013","article-title":"Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms","volume":"18 Suppl 1","author":"Kl\u00f6ppel","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2025091917505474400_lvaf159-B6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"issue":"7","key":"2025091917505474400_lvaf159-B7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.5858\/arpa.2019-0654-RA","article-title":"Pancreatic neuroendocrine neoplasms: landscape and horizon","volume":"144","author":"Tang","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"2025091917505474400_lvaf159-B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s12022-020-09628-z","article-title":"Morphologic variants of pancreatic neuroendocrine tumors: clinicopathologic analysis and prognostic stratification","volume":"31","author":"Xue","year":"2020","journal-title":"Endocr Pathol"},{"issue":"12","key":"2025091917505474400_lvaf159-B9","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"2025091917505474400_lvaf159-B10","first-page":"417","volume-title":"WHO Classification of Tumours of the Digestive System","author":"Rindi","year":"2010"},{"issue":"29","key":"2025091917505474400_lvaf159-B11","doi-asserted-by":"publisher","first-page":"27566","DOI":"10.18632\/oncotarget.4491","article-title":"Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy","volume":"6","author":"Kaemmerer","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"2025091917505474400_lvaf159-B12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2025091917505474400_lvaf159-B13","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.humpath.2015.08.006","article-title":"Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor","volume":"46","author":"Takizawa","year":"2015","journal-title":"Hum Pathol"},{"issue":"2","key":"2025091917505474400_lvaf159-B14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2025091917505474400_lvaf159-B15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/cancers13040643","article-title":"Biomarkers of response to etoposide-platinum chemotherapy in patients with grade 3 neuroendocrine neoplasms","volume":"13","author":"Lacombe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025091917505474400_lvaf159-B16","volume-title":"WHO Classification of Tumours of the Digestive System","author":"Bosman","year":"2010"},{"key":"2025091917505474400_lvaf159-B17","volume-title":"WHO Classification of Tumours of Endocrine Organs","author":"Lloyd","year":"2017"},{"issue":"18","key":"2025091917505474400_lvaf159-B18","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025091917505474400_lvaf159-B19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/PAS.0000000000000169","article-title":"Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases","volume":"38","author":"Basturk","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2025091917505474400_lvaf159-B20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12022-021-09662-5","article-title":"Molecular pathology of well-differentiated gastro-entero-pancreatic neuroendocrine tumors","volume":"32","author":"Asa","year":"2021","journal-title":"Endocr Pathol"},{"issue":"1","key":"2025091917505474400_lvaf159-B21","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1038\/s41598-019-39607-2","article-title":"Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin","volume":"9","author":"Mai","year":"2019","journal-title":"Sci Rep"},{"key":"2025091917505474400_lvaf159-B22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fendo.2018.00146","article-title":"Octreotide does not inhibit proliferation in five neuroendocrine tumor cell lines","volume":"9","author":"Exner","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2025091917505474400_lvaf159-B23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000335595","article-title":"ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms","volume":"95","author":"Delle Fave","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"28","key":"2025091917505474400_lvaf159-B24","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025091917505474400_lvaf159-B25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"2-3","key":"2025091917505474400_lvaf159-B26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000180970","article-title":"Somatostatin receptors in normal and tumoral tissue","volume":"29","author":"Reubi","year":"1988","journal-title":"Horm Res"},{"issue":"6","key":"2025091917505474400_lvaf159-B27","doi-asserted-by":"publisher","first-page":"e13309","DOI":"10.1111\/jne.13309","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours","volume":"35","author":"Rinke","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"40","key":"2025091917505474400_lvaf159-B28","doi-asserted-by":"publisher","first-page":"e1281","DOI":"10.1097\/MD.0000000000001281","article-title":"Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors","volume":"94","author":"Mehta","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2025091917505474400_lvaf159-B29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000454761","article-title":"Neuroendocrine cancer, therapeutic strategies in G3 cancers","volume":"95","author":"Rinke","year":"2017","journal-title":"Digestion"},{"issue":"3","key":"2025091917505474400_lvaf159-B30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/1541-7786.MCR-17-0163","article-title":"Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model","volume":"16","author":"Benten","year":"2018","journal-title":"Mol Cancer Res"},{"issue":"6","key":"2025091917505474400_lvaf159-B31","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1210\/jc.2006-0110","article-title":"The functional characterization of normal and neoplastic human enterochromaffin cells","volume":"91","author":"Modlin","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025091917505474400_lvaf159-B32","first-page":"1951","article-title":"Establishment and characterization of three novel cell lines\u2014P-STS, L-STS, H-STS\u2014derived from a human metastatic midgut carcinoid","volume":"29","author":"Pfragner","year":"2009","journal-title":"Anticancer Res"},{"issue":"10","key":"2025091917505474400_lvaf159-B33","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s41588-019-0509-5","article-title":"Reply to \u2018H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines\u2019","volume":"51","author":"Alvarez","year":"2019","journal-title":"Nat Genet"},{"issue":"7-8","key":"2025091917505474400_lvaf159-B34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cancergen.2015.04.002","article-title":"Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines","volume":"208","author":"Boora","year":"2015","journal-title":"Cancer Genet"},{"issue":"2","key":"2025091917505474400_lvaf159-B35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/JME-14-0304","article-title":"Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1","volume":"54","author":"Vandamme","year":"2015","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"2025091917505474400_lvaf159-B36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000338793","article-title":"The role of cell lines in the study of neuroendocrine tumors","volume":"96","author":"Grozinsky-Glasberg","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"4","key":"2025091917505474400_lvaf159-B37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/MNM.0000000000001666","article-title":"Wnt\/\u03b2-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells","volume":"44","author":"Weich","year":"2023","journal-title":"Nucl Med Commun"},{"issue":"11","key":"2025091917505474400_lvaf159-B38","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2967\/jnumed.115.165092","article-title":"Upregulation of key molecules for targeted imaging and therapy","volume":"57","author":"Taelman","year":"2016","journal-title":"J Nucl Med"},{"issue":"4","key":"2025091917505474400_lvaf159-B39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/RLU.0000000000004591","article-title":"Somatostatin receptor-directed PET\/CT for therapeutic decision-making and disease control in patients affected with small cell lung cancer","volume":"48","author":"Serfling","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"6","key":"2025091917505474400_lvaf159-B40","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1530\/EJE-20-1423","article-title":"A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden","volume":"184","author":"Landwehr","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025091917505474400_lvaf159-B41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ijc.10098","article-title":"Modulation of HMG-N2 binding to chromatin by butyrate-induced acetylation in human colon adenocarcinoma cells","volume":"97","author":"Luhrs","year":"2002","journal-title":"Int J Cancer"},{"issue":"2","key":"2025091917505474400_lvaf159-B42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/diagnostics11020367","article-title":"Wnt\/\u03b2-catenin signaling regulates CXCR4 expression and [(68)Ga] pentixafor internalization in neuroendocrine tumor cells","volume":"11","author":"Weich","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"25","key":"2025091917505474400_lvaf159-B43","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1242\/jcs.01532","article-title":"The lamin CxxM motif promotes nuclear membrane growth","volume":"117","author":"Pru\u0308fert","year":"2004","journal-title":"J Cell Sci"},{"issue":"2","key":"2025091917505474400_lvaf159-B44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","article-title":"ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells","volume":"180","author":"Liu","year":"2012","journal-title":"Am J Pathol"},{"issue":"5","key":"2025091917505474400_lvaf159-B45","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000434723","article-title":"Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-octreotate-capecitabine-temozolomide radiopeptide chemotherapy","volume":"103","author":"Claringbold","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"11","key":"2025091917505474400_lvaf159-B46","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2337\/diab.43.11.1326","article-title":"STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells","volume":"43","author":"Schnedl","year":"1994","journal-title":"Diabetes"},{"issue":"1","key":"2025091917505474400_lvaf159-B47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1535-7163.MCT-17-0325","article-title":"Combinatorial treatment with mTOR inhibitors and streptozotocin leads to synergistic in vitro and in vivo antitumor effects in insulinoma cells","volume":"17","author":"Bollard","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"7738","key":"2025091917505474400_lvaf159-B48","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1038\/s41586-018-0722-x","article-title":"Addendum: the cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"565","author":"Barretina","year":"2019","journal-title":"Nature"},{"issue":"16","key":"2025091917505474400_lvaf159-B49","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1158\/1078-0432.CCR-06-2723","article-title":"The development and characterization of a human midgut carcinoid cell line","volume":"13","author":"Van Buren","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025091917505474400_lvaf159-B50","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0002-9440(10)64017-5","article-title":"A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake","volume":"158","author":"K\u00f6lby","year":"2001","journal-title":"Am J Pathol"},{"issue":"10","key":"2025091917505474400_lvaf159-B51","doi-asserted-by":"publisher","first-page":"e48411","DOI":"10.1371\/journal.pone.0048411","article-title":"The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"2025091917505474400_lvaf159-B52","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/cancers12030691","article-title":"A comprehensive molecular characterization of the pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1","volume":"12","author":"Luley","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025091917505474400_lvaf159-B53","first-page":"596","article-title":"Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma","volume":"71","author":"Kaku","year":"1980","journal-title":"Gan"},{"issue":"2","key":"2025091917505474400_lvaf159-B54","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0016-5085(91)90004-5","article-title":"Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth","volume":"101","author":"Evers","year":"1991","journal-title":"Gastroenterology"},{"issue":"4","key":"2025091917505474400_lvaf159-B55","doi-asserted-by":"publisher","first-page":"X1","DOI":"10.1530\/ERC-17-0445e","article-title":"The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines","volume":"25","author":"Hofving","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2025091917505474400_lvaf159-B56","doi-asserted-by":"publisher","first-page":"e13249","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"2025091917505474400_lvaf159-B57","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"2025091917505474400_lvaf159-B58","doi-asserted-by":"publisher","first-page":"162","DOI":"10.15403\/jgld-4654","article-title":"NET G3 vs NEC: p53 and Rb1 immunolabeling in high-grade gastrointestinal neuroendocrine neoplasms\u2014is it enough for the differential diagnosis?","volume":"32","author":"Dinu","year":"2023","journal-title":"J Gastrointestin Liver Dis"},{"issue":"2","key":"2025091917505474400_lvaf159-B59","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1210\/er.2018-00160","article-title":"Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms","volume":"40","author":"Mafficini","year":"2019","journal-title":"Endocr Rev"},{"issue":"2","key":"2025091917505474400_lvaf159-B60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12022-021-09676-z","article-title":"Challenges in high-grade neuroendocrine neoplasms and mixed neuroendocrine\/non-neuroendocrine neoplasms","volume":"32","author":"La Rosa","year":"2021","journal-title":"Endocr Pathol"},{"issue":"3","key":"2025091917505474400_lvaf159-B61","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/PAS.0b013e3181ce1447","article-title":"Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set","volume":"34","author":"Klimstra","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2025091917505474400_lvaf159-B62","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3390\/diagnostics11040605","article-title":"CXCR4-directed PET\/CT in patients with newly diagnosed neuroendocrine carcinomas","volume":"11","author":"Weich","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"2025091917505474400_lvaf159-B63","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1093\/carcin\/bgt282","article-title":"Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer","volume":"34","author":"Toiyama","year":"2013","journal-title":"Carcinogenesis"},{"issue":"2","key":"2025091917505474400_lvaf159-B64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1590\/S1677-5538.IBJU.2014.02.07","article-title":"Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer","volume":"40","author":"Zhao","year":"2014","journal-title":"Int Braz J Urol"},{"key":"2025091917505474400_lvaf159-B65","doi-asserted-by":"publisher","first-page":"917","DOI":"10.17179\/excli2020-1946","article-title":"Significance of E-cadherin and vimentin as epithelial-mesenchymal transition markers in colorectal carcinoma prognosis","volume":"19","author":"Niknami","year":"2020","journal-title":"EXCLI J"},{"issue":"20","key":"2025091917505474400_lvaf159-B66","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.3390\/ijms21207624","article-title":"Role of cadherins in cancer-A review","volume":"21","author":"Kaszak","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2025091917505474400_lvaf159-B67","doi-asserted-by":"publisher","first-page":"e57393","DOI":"10.1371\/journal.pone.0057393","article-title":"Down-regulation of canonical and up-regulation of non-canonical Wnt signalling in the carcinogenic process of squamous cell lung carcinoma","volume":"8","author":"Bartis","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2025091917505474400_lvaf159-B68","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12885-021-08062-6","article-title":"High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"issue":"35","key":"2025091917505474400_lvaf159-B69","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1038\/s41388-018-0304-2","article-title":"E-cadherin in contact inhibition and cancer","volume":"37","author":"Mendonsa","year":"2018","journal-title":"Oncogene"},{"issue":"6","key":"2025091917505474400_lvaf159-B70","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","article-title":"Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis","volume":"14","author":"Yang","year":"2008","journal-title":"Dev Cell"},{"issue":"5","key":"2025091917505474400_lvaf159-B71","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/his.14178","article-title":"Looking into digestive mixed neuroendocrine\u2014nonneuroendocrine neoplasms: subtypes, prognosis, and predictive factors","volume":"77","author":"Uccella","year":"2020","journal-title":"Histopathology"},{"issue":"2","key":"2025091917505474400_lvaf159-B72","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/endrev\/bnz004","article-title":"Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms","volume":"41","author":"Hofland","year":"2020","journal-title":"Endocr Rev"},{"issue":"9","key":"2025091917505474400_lvaf159-B73","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","article-title":"A practical approach to the classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the pancreas","volume":"40","author":"Tang","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2025091917505474400_lvaf159-B74","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1053\/j.gastro.2010.07.002","article-title":"Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy","volume":"139","author":"\u00d6berg","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"2025091917505474400_lvaf159-B75","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11307-022-01717-1","article-title":"Impact of tumor burden on normal organ distribution in patients imaged with CXCR4-targeted [(68)Ga]Ga-PentixaFor PET\/CT","volume":"24","author":"Serfling","year":"2022","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"2025091917505474400_lvaf159-B76","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.7150\/thno.18754","article-title":"Imaging of chemokine receptor 4 expression in neuroendocrine tumors\u2014a triple tracer comparative approach","volume":"7","author":"Werner","year":"2017","journal-title":"Theranostics"},{"issue":"18","key":"2025091917505474400_lvaf159-B77","doi-asserted-by":"publisher","first-page":"8264","DOI":"10.7150\/thno.45537","article-title":"A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency","volume":"10","author":"Osl","year":"2020","journal-title":"Theranostics"},{"issue":"8","key":"2025091917505474400_lvaf159-B78","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s12149-018-1290-8","article-title":"CXCR4-directed theranostics in oncology and inflammation","volume":"32","author":"Kircher","year":"2018","journal-title":"Ann Nucl Med"},{"issue":"11","key":"2025091917505474400_lvaf159-B79","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2967\/jnumed.121.263693","article-title":"Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using (68)Ga-pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J Nucl Med"},{"issue":"20","key":"2025091917505474400_lvaf159-B80","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1055\/a-0801-3686","article-title":"Neues zur Therapie von neuroendokrinen Tumoren des gastroenteropankreatischen systems","volume":"144","author":"Auernhammer","year":"2019","journal-title":"Dtsch Med Wochenschr"},{"issue":"3-4","key":"2025091917505474400_lvaf159-B81","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000439086","article-title":"Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity","volume":"103","author":"Clewemar Antonodimitrakis","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2025091917505474400_lvaf159-B82","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"10022","key":"2025091917505474400_lvaf159-B83","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"2025091917505474400_lvaf159-B84","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"2025091917505474400_lvaf159-B85","doi-asserted-by":"publisher","first-page":"627819","DOI":"10.3389\/fendo.2021.627819","article-title":"Patient-derived organoid models of human neuroendocrine carcinoma","volume":"12","author":"Dijkstra","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7643","key":"2025091917505474400_lvaf159-B86","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"issue":"7677","key":"2025091917505474400_lvaf159-B87","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature24026","article-title":"Corrigendum: whole-genome landscape of pancreatic neuroendocrine tumours","volume":"550","author":"Scarpa","year":"2017","journal-title":"Nature"},{"issue":"5","key":"2025091917505474400_lvaf159-B88","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00280-009-1094-6","article-title":"Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors","volume":"65","author":"Shida","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2025091917505474400_lvaf159-B89","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2174\/138920111795164048","article-title":"Revisiting the ABCs of multidrug resistance in cancer chemotherapy","volume":"12","author":"Tiwari","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"2025091917505474400_lvaf159-B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2014.10.001","article-title":"Apical ABC transporters and cancer chemotherapeutic drug disposition","volume":"125","author":"Durmus","year":"2015","journal-title":"Adv Cancer Res"},{"issue":"15","key":"2025091917505474400_lvaf159-B91","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/1759-7714.14527","article-title":"Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer","volume":"13","author":"Omori","year":"2022","journal-title":"Thorac Cancer"},{"key":"2025091917505474400_lvaf159-B92","doi-asserted-by":"publisher","first-page":"648407","DOI":"10.3389\/fphar.2021.648407","article-title":"Clinically-relevant ABC transporter for anti-cancer drug resistance","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Pharmacol"},{"issue":"12","key":"2025091917505474400_lvaf159-B93","doi-asserted-by":"publisher","first-page":"e0143822","DOI":"10.1371\/journal.pone.0143822","article-title":"Streptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms--predictive and prognostic markers for treatment stratification","volume":"10","author":"Krug","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"2025091917505474400_lvaf159-B94","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"issue":"1","key":"2025091917505474400_lvaf159-B95","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1038\/s41467-019-13196-0","article-title":"On-target restoration of a split T cell-engaging antibody for precision immunotherapy","volume":"10","author":"Banaszek","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"2025091917505474400_lvaf159-B96","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s42003-020-01558-0","article-title":"Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments","volume":"4","author":"Geis","year":"2021","journal-title":"Commun Biol"},{"issue":"3","key":"2025091917505474400_lvaf159-B97","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.15096","article-title":"Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy","volume":"184","author":"Lapa","year":"2019","journal-title":"Br J Haematol"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/3\/359\/64286156\/lvaf159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/3\/359\/64286156\/lvaf159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:51:13Z","timestamp":1758318673000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/3\/359\/8255912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf159","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,29]]}}}